C/EPBα is a known tumor suppressor mutated in about 10% of AML (Gombart et al., 2002; Pabst et al., 2001) and is a direct target of NR4A1 and NR4A3 (Freire and Conneely, 2018). This evidence concerns the gene NR4A3 and acute myeloid leukemia.